Detection of small hepatocellular carcinoma: Intraindividual comparison of gadoxetic acid-enhanced MRI at 3.0 and 1.5 T

Investigative Radiology

Volumn 46, Issue 6, 2011, Pages 383-389

  Kim, Young Kon ^a   Kim, Chong Soo ^a   Han, Young Min ^a   Yu, Hee Chul ^b   Choi, Dongil ^a  

^a Jeonbuk National University Medical School and Hospital   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

3.0 T; contrast agents; hepatocellular carcinoma; Liver; magnetic resonance imaging

Indexed keywords

GADOXETIC ACID;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; IMAGE ANALYSIS; LIVER CELL; LIVER CELL CARCINOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIGNAL NOISE RATIO;

EID: 79955864983     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e318217b8fb     Document Type: Article

References (35)

1. Jung G, Breuer J, Poll LW, et al. Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Acta Ra-diol. 2006;47:15-23. (Pubitemid 43177525)
2. Asbach P, Warmuth C, Stemmer A, et al. High spatial resolution T1-weighted MR imaging of liver and biliary tract during uptake phase of a hepatocyte-specific contrast medium. Invest Radiol. 2008;43:809-815.
3. Zech CJ, Grazioli L, Breuer J, et al. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol. 2008;43:504-511.
4. Zech CJ, Vos B, Nordell A, et al. Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest Radiol. 2009;44:305-310.
5. Halavaara J, Breuer J, Ayuso C, et al. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT-a multicenter trial. J Comput Assist Tomogr. 2006;30:345-354. (Pubitemid 43922248)
6. Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellu-lar carcinoma and chronic liver disease. Invest Radiol. 2010;45:133-141.
7. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology. 2004;230:266-275. (Pubitemid 37549812)
8. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol. 2008;18:457-467. (Pubitemid 351248177)
9. Kim YK, Kim CS, Han YM, et al. Detection of hepatocellular carcinoma: gadoxetic acid-enhanced 3-dimensional magnetic resonance imaging versus multi-detector row computed tomography. J Comput Assist Tomogr. 2009; 33:844-850.
10. Kim YK, Kim CS, Han YM, et al. Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced MR imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced MR imaging? Invest Radiol. 2010;45;740-746.
11. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724. (Pubitemid 41546838)
12. Chang KJ, Kamel IR, Macura KJ, et al. 3.0-T MR imaging of the abdomen: comparison with 1. 5 T. Radiographics. 2008;28:1983-1998.
13. Yoo HJ, Lee JM, Lee MW, et al. Hepatocellular carcinoma in cirrhotic liver: double-contrast-enhanced, high-resolution 3. 0T-MR imaging with pathologic correlation.InvestRadiol. 2008;43:538-546.
14. Yoon MA, Kim SH, Park HS, et al. Value of dual contrast liver MRI at 3.0 T in differentiating well-differentiated hepatocellular carcinomas from dys-plastic nodules: preliminary results of multivariate analysis. Invest Radiol. 2009;44:641-649.
15. Elster AD. How much contrast is enough? Dependence of enhancement on field strength and MR pulse sequence. Eur Radiol. 1997;7(suppl 5):276-280.
16. Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepato-carcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol. 1991;22:172-178.
17. Kobayashi M, Ikeda K, Hosaka T, et al. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer. 2006;106:636-647. (Pubitemid 43157628)
18. Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol. 2009;44(suppl 19):112-118.
19. World Medical Association Declaration of Helsinki:ethical principles for medical research involving human subjects. JAMA. 2000;284:3043-3045.
20. Sun HY, Lee JM, Shin CI, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (
21. Obuchowski NA, McClish DK. Sample size determination for diagnostic accuracy studies involving binormal ROC curve indices. Stat Med. 1997;16: 1529-1542. (Pubitemid 27322656)
22. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the esophagus for bleeding esophageal varices. Br J Surg. 1973;60:646-649.
23. Edmondson HA, Steiner PE. Primary carcinoma of liver: study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462-503.
24. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. (Pubitemid 43112690)
25. Lencioni R, Pinto F, Armillotta N, et al. Intrahepatic metastatic nodules of hepatocellular carcinoma detected at lipiodol-CT: imaging-pathologic correlation. Abdom Imaging. 1997;22:253-258.
26. Tanimoto A, Lee JM, Murakami T, et al. Consensus report of the 2nd International Forum for Liver MRI. Eur Radiol. 2009;19(suppl 5):S975-S989.
27. Motosugi U, Ichikawa T, Sou H, et al. Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI). JMagn Reson Imaging. 2009;30:849-854.
28. Chakraborty DP, Winter LH. Free-response methodology: alternate analysis and a new observer-performance experiment. Radiology. 1990;74:873-881. (Pubitemid 20089690)
29. Metz CE. ROC methodology in radiologic imaging. Invest Radiol. 1986;21:720-733. (Pubitemid 16015664)
30. Rao JN, Scott AJ. A simple method for the analysis of clustered binary data. Biometrics. 1992;48:577-585.
31. Kim YK, Lee YH, Kwak HS, et al. Clinical implication of small (<20 mm) enhancing hepatic nodules observed only during three-dimensional gado-benate dimeglumine-enhanced hepatic arterial-phase MRI of the hepatitis B virus-induced mild cirrhosis. Clin Imaging. 2008;32:453-459.
32. Holland AE, Hecht EM, Hahn WY, et al. Importance of small (< or = 20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole ex-planted liver. Radiology. 2005;237:938-944.
33. Leoni S, Piscaglia F, Golfieri R, et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol. 2010;105:599-609.
34. Tschirch FT, Struwe A, Petrowsky H, et al. Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol. 2008;18:1577-1586.
35. Ryeom HK, Kim SH, Kim JY, et al. Quantitative evaluation of liver function with MRI using Gd-EOB-DTPA. Korean J Radiol. 2004;5:231-239.